Cantor Fitzgerald Reaffirms “Overweight” Rating for Perspective Therapeutics (NYSE:CATX)

Cantor Fitzgerald reaffirmed their overweight rating on shares of Perspective Therapeutics (NYSE:CATX) in a report released on Tuesday morning, Benzinga reports.

Several other brokerages also recently weighed in on CATX. B. Riley upped their target price on Perspective Therapeutics from $12.00 to $17.00 and gave the stock a buy rating in a research note on Tuesday, April 9th. Lifesci Capital reissued an outperform rating on shares of Perspective Therapeutics in a research note on Monday, May 6th. Oppenheimer reissued an outperform rating on shares of Perspective Therapeutics in a research note on Tuesday, June 18th. Finally, Royal Bank of Canada reissued an outperform rating and issued a $30.00 price objective on shares of Perspective Therapeutics in a research note on Friday, June 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of Buy and a consensus target price of $19.00.

Perspective Therapeutics Stock Up 3.8 %

Shares of CATX stock opened at $9.87 on Tuesday. The company has a current ratio of 12.98, a quick ratio of 12.98 and a debt-to-equity ratio of 0.01. Perspective Therapeutics has a 1-year low of $2.05 and a 1-year high of $19.05.

Perspective Therapeutics (NYSE:CATX) last announced its earnings results on Wednesday, May 15th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.10. The business had revenue of $0.33 million during the quarter. Perspective Therapeutics had a negative return on equity of 46.38% and a negative net margin of 302.70%. Research analysts anticipate that Perspective Therapeutics will post -1.01 EPS for the current fiscal year.

Insider Activity at Perspective Therapeutics

In related news, Director Robert F. Williamson III bought 3,003 shares of the business’s stock in a transaction on Wednesday, May 29th. The stock was acquired at an average cost of $13.30 per share, with a total value of $39,939.90. Following the purchase, the director now directly owns 36,879 shares of the company’s stock, valued at $490,490.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, Director Lori A. Woods bought 4,587 shares of the business’s stock in a transaction on Friday, June 14th. The stock was acquired at an average cost of $10.90 per share, with a total value of $49,998.30. Following the purchase, the director now directly owns 159,985 shares of the company’s stock, valued at $1,743,836.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Robert F. Williamson III bought 3,003 shares of the business’s stock in a transaction on Wednesday, May 29th. The stock was bought at an average cost of $13.30 per share, with a total value of $39,939.90. Following the completion of the purchase, the director now directly owns 36,879 shares in the company, valued at $490,490.70. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 30,814 shares of company stock valued at $385,487. 3.52% of the stock is owned by insiders.

Institutional Trading of Perspective Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. ZWJ Investment Counsel Inc. acquired a new stake in shares of Perspective Therapeutics in the 1st quarter worth $26,000. Simplicity Wealth LLC purchased a new position in shares of Perspective Therapeutics during the 1st quarter worth $40,000. Bleakley Financial Group LLC purchased a new position in shares of Perspective Therapeutics during the 1st quarter worth $40,000. RIA Advisory Group LLC grew its holdings in shares of Perspective Therapeutics by 1,313.4% during the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock worth $127,000 after purchasing an additional 99,293 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Perspective Therapeutics during the 1st quarter worth $138,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.